Clinical Trial Update: Oblimersen and Imatinib Mesylate in Treating Patients With Advanced Gastrointestinal Stromal Tumors That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

This Phase 2 trial evaluated oblimersen in combination with imatinib mesylate for advanced, unresectable gastrointestinal stromal tumors and the study was termi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Stromal Tumor

Drugs mentioned

• Genasense (oblimersen)
• Gleevec (Imatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Gastrointestinal Stromal Tumor | Phase 2 | Status: TERMINATED